Literature DB >> 17761984

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.

Michael J Callahan1, Christopher P Crum, Fabiola Medeiros, David W Kindelberger, Julia A Elvin, Judy E Garber, Colleen M Feltmate, Ross S Berkowitz, Michael G Muto.   

Abstract

PURPOSE: To review the frequency and location of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations.
METHODS: Medical records and pathology findings were reviewed from BRCA-positive women undergoing prophylactic surgery for ovarian cancer risk reduction who underwent complete examination of the adnexa. Patients undergoing this procedure between January 1999 and January 2007 were identified.
RESULTS: From January 1999 to January 2007, 122 BRCA-positive patients underwent prophylactic surgery in the Division of Gynecologic Oncology at Brigham and Women's Hospital. The median age was 46.5 years (range, 33 to 76 years). Seven (5.7%) were found to have an early malignancy in the upper genital tract and all patients were age > or = 44 years at diagnosis. Of seven consecutive cancers culled between January 1999 and January 2007, all (100%) originated in the fimbrial or ampullary region of the tube; six had an early (intraepithelial) component. Two were associated with surface implants on the ovary and two required repeated sectioning to detect microscopic carcinomas in the fimbria.
CONCLUSION: The distal fallopian tube seems to be the dominant site of origin for early malignancies detected in approximately 6% of women undergoing ovarian cancer risk-reduction surgery. The greatest proportion of serous cancer risk in BRCA mutation-positive women should be assigned to the fimbria rather than the ovary, and future clinical and research protocols should employ thorough examination of the fimbria, including multiple sections from each tissue block, to maximize detection of early malignancies in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761984     DOI: 10.1200/JCO.2007.12.2622

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  145 in total

1.  Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.

Authors:  Weiwei Shan; Imelda Mercado-Uribe; Jing Zhang; Daniel Rosen; Shiwu Zhang; Jianjun Wei; Jinsong Liu
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

2.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

3.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

4.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

5.  Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal?

Authors:  T J Herzog; H E Dinkelspiel
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

6.  Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract.

Authors:  Jean S Fleming; H James McQuillan; Melanie J Millier; Grant C Sellar
Journal:  Reproduction       Date:  2009-01-27       Impact factor: 3.906

7.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

Review 8.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

Review 9.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

10.  Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.

Authors:  Talayeh S Ghezelayagh; Lauren E Stewart; Barbara M Norquist; Deborah J Bowen; Vivian Yu; Kathy J Agnew; Kathryn P Pennington; Elizabeth M Swisher
Journal:  Fam Cancer       Date:  2020-02-24       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.